Moderate To Severe Atopic Dermatitis Pipeline Outlook 2025: Insights Into Therapies, Research, And Market Potential

DelveInsight's,“ Moderate to Severe Atopic Dermatitis Pipeline Insight 2025 ” report provides comprehensive insights about 45+ companies and 50+ pipeline drugs in the Moderate to Severe Atopic Dermatitis pipeline landscape. It covers the Moderate to Severe Atopic Dermatitis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Moderate to Severe Atopic Dermatitis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the Moderate to Severe Atopic Dermatitis Pipeline? Click here to explore the therapies and trials making headlines @ Moderate to Severe Atopic Dermatitis Pipeline Outlook Report

Key Takeaways from the Moderate to Severe Atopic Dermatitis Pipeline Report

• On 29 August 2025, AbbVie conducted a study is to evaluate the clinical efficacy and safety of single therapies and/or combination therapies for moderate to severe AD through multiple substudies. This study will consist of multiple sub-studies, Sub-Study 1 will have a randomized, placebo controlled period 1 followed by a lutikizumab treatment period 2 enrolling 80 participants at a 1 to 1 ratio.
• On 29 August 2025, Evommune Inc . announced a Phase 2a efficacy and safety study of intravenous EVO301 in adults with moderate to severe atopic dermatitis.
• On 27 August 2025, medac GmbH organized a Phase 3 clinical trial to Evaluate the Efficacy and Safety of Subcutaneous Methotrexate Versus Placebo in Moderate to Severe Atopic Dermatitis.
• DelveInsight's Moderate to Severe Atopic Dermatitis pipeline report depicts a robust space with 45+ active players working to develop 50+ pipeline therapies for Moderate to Severe Atopic Dermatitis treatment.
• The leading Moderate to Severe Atopic Dermatitis Companies such as Jiangsu Vcare Pharmaceutical Technology Co., LTD, Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd., Nektar Therapeutics, E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd., Corvus Pharmaceuticals, Inc., UCB Biopharma SRL, Tavotek Biotherapeutics, Guangdong Hengrui Pharmaceutical Co., Ltd., SCM Lifescience Co., LTD., Sanofi, Amgen, Qurient Co., Ltd., Sun Pharmaceutical Industries Limited, Pfizer, UNION Therapeutics, Bio-Thera Solutions, Medac GmbH, Eli Lilly and Company, AbbVie, Lynk Pharmaceuticals Co., Ltd., LEO Pharma, Guangzhou JOYO Pharma Co., Ltd., Beijing InnoCare Pharma Tech Co., Ltd., Oneness Biotech Co., Ltd., Evommune, Inc . and others.
• Promising Moderate to Severe Atopic Dermatitis Therapies such as Rocatinlimab, CM310, Nemolizumab, Rezpegaldesleukin, SHR-1819, CBP-201, Methotrexate , and others.

Want to know which companies are leading innovation in Non-Muscle Invasive Bladder Cancer? Dive into the full pipeline insights @ Moderate to Severe Atopic Dermatitis Clinical Trials Assessment

The Moderate to Severe Atopic Dermatitis Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Moderate to Severe Atopic Dermatitis Pipeline Report also highlights the unmet needs with respect to the development of Moderate to Severe Atopic Dermatitis.

Moderate to Severe Atopic Dermatitis Overview

Non-muscle invasive bladder cancer (Moderate to Severe Atopic Dermatitis) is cancer found in the tissue that lines the inner surface of the bladder. The bladder muscle is not involved. Bladder cancer is the 6th most common cancer in the United States. Nearly 81,000 people will be diagnosed in the United States with bladder cancer in 2020. Bladder cancer is more common in males than females.

Moderate to Severe Atopic Dermatitis Emerging Drugs Profile

• VC005: Jiangsu vcare pharmaceutical technology co., LTD

VC005 is a new, highly potent, and highly selective second-generation JAK1 inhibitor independently developed by Jiangsu Vcare. The drug selectively inhibits JAK1 to reduce inflammation and the activation of immune cells, thereby achieving the effect of treating inflammatory and autoimmune diseases. Compared to the marketed drug UpAtopic dermatitisacitinib, VC005 has lower JAK2 inhibitory activity based on in vitro kinase assay results, which may help alleviate a series of safety issues caused by excessive JAK2 inhibition in the clinic. VC005 has been developed as oral tablets which demonstrated positive top-line results in treating moderate to severe atopic dermatitis in clinical studies. Currently, the drug is in Phase III stage of its development for the treatment of Moderate to Severe Atopic Dermatitis.

• TQH2722: Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.

TQH2722 is a humanized monoclonal antibody developed by Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd., specifically targeting the interleukin 4 receptor alpha (IL4Rα). This innovative therapeutic agent achieves dual-blockAtopic dermatitise of interleukin-4 (IL-4) and interleukin-13 (IL-13) signaling, effectively inhibiting the T-helper cell type 2 (Th2) immune pathway. By targeting this inflammatory mechanism, TQH2722 aims to provide a promising treatment approach for moderate to severe atopic dermatitis, with early clinical trials demonstrating a well-tolerated safety profile and potential for managing Th2-mediated inflammatory conditions. Currently, the drug is in Phase III stage of its clinical trial for the treatment of Moderate to Severe Atopic Dermatitis.

• Rezpegaldesleukin: Nektar Therapeutics

REZPEG (NKTR-358) is a novel first-in-class regulatory T (Treg) cell stimulator designed to Atopic dermatitisdress the imbalance in the immune system underlying autoimmune disorders and chronic inflammatory conditions. Research suggests that suboptimal levels of Treg cells, powerful inhibitory immune cells, and lack of Treg cell activity may underlie the development of autoimmune and inflammatory diseases, including lupus and psoriasis. REZPEG (NKTR-358) works by targeting the IL-2 receptor complex and preferentially stimulating the proliferation of Treg cells without stimulating cytotoxic CD8+ T and CD4+ T cells, which drive autoimmune disease. Activation of Tregs suppresses disease-causing T cells and restores the body's self-tolerance mechanisms. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Moderate to Severe Atopic Dermatitis.

• QY201: E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.

QY201 tablets are a new generation of highly active JAK1/TYK2 dual-target inhibitors independently developed by Enitiate Biologicals, and are highly selective for JAK2. By blocking the JAK-STAT pathway through inhibition of JAK activity, QY201 reduces the expression of pro-inflammatory cytokines, thereby exerting therapeutic effects on autoimmune diseases such as atopic dermatitis and psoriasis. QY201 inhibits both JAK1 and TYK2 with high selectivity and activity, signaling that the risk of toxicity due to QY201 inhibition of other kinase targets is low. QY201 tablets can rapidly stop itching, clear skin lesions, and improve the quality of life of patients with moderate-to-severe atopic dermatitis. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Moderate to Severe Atopic Dermatitis.

• Soquelitinib: Corvus Pharmaceuticals, Inc.

Soquelitinib is an innovative investigational small molecule drug developed by Corvus Pharmaceuticals, designed to selectively inhibit interleukin-2-inducible T cell kinase (ITK). This novel therapeutic agent targets the complex immunological mechanisms underlying atopic dermatitis by modulating T cell differentiation and immune response. Specifically, Soquelitinib works by inducing the generation of Th1 helper cells while simultaneously blocking the development of Th2 and Th17 cells, which are critically involved in the pathogenesis of inflammatory and allergic conditions. By strategically inhibiting specific molecular targets in T cells, soquelitinib offers a potential breakthrough in managing moderate to severe atopic dermatitis through its unique immunomodulatory approach. Currently, the drug is in Phase I stage of its clinical trial for the treatment of Moderate to Severe Atopic Dermatitis.

Moderate to Severe Atopic Dermatitis Market Drivers

• Increasing Moderate to Severe Atopic Dermatitis Prevalence
• Advancements in Bladder Cancer Treatment

Moderate to Severe Atopic Dermatitis Market Barriers

• Increasing use of Biologics and Targeted Therapies
• High Cost associated with the disease

The Moderate to Severe Atopic Dermatitis Pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Moderate to Severe Atopic Dermatitis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Moderate to Severe Atopic Dermatitis Treatment.
• Moderate to Severe Atopic Dermatitis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Moderate to Severe Atopic Dermatitis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Moderate to Severe Atopic Dermatitis market.

If you're tracking ongoing Moderate to Severe Atopic Dermatitis clinical trials, this press release is a must-read. Tap to see the breakthroughs @ Moderate to Severe Atopic Dermatitis Treatment Drugs

Moderate to Severe Atopic Dermatitis Companies

CG Oncology, Janssen Research & Development, LLC, Tyra Biosciences, Inc, UroGen Pharma Ltd., Prokarium Ltd, Protara Therapeutics, ImmVira Pharma Co. Ltd, Trigone Pharma Ltd., Hoffmann-La Roche, Aura Biosciences, enGene Holdings Inc., Atonco Pharma and others.

Moderate to Severe Atopic Dermatitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Moderate to Severe Atopic Dermatitis Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

From emerging drug candidates to competitive intelligence, the Moderate to Severe Atopic Dermatitis Pipeline Report covers it all – check it out now @ Moderate to Severe Atopic Dermatitis Market Drivers and Barriers, and Future Perspectives

Scope of the Moderate to Severe Atopic Dermatitis Pipeline Report

• Coverage- Global
• Moderate to Severe Atopic Dermatitis Companies- CG Oncology, Janssen Research & Development, LLC, Tyra Biosciences, Inc, UroGen Pharma Ltd., Prokarium Ltd, Protara Therapeutics, ImmVira Pharma Co. Ltd, Trigone Pharma Ltd., Hoffmann-La Roche, Aura Biosciences, enGene Holdings Inc., Atonco Pharma and others.
• Moderate to Severe Atopic Dermatitis Therapies- PF-06801591, Bacillus Calmette-Guerin, CG0070, Gemcitabine, APL-1202 treatment, Durvalumab, eRapa, Epirubicin Hydrochloride, Cabazitaxel, Gemcitabine, Cisplatin and others.
• Moderate to Severe Atopic Dermatitis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Moderate to Severe Atopic Dermatitis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Stay ahead in oncology research – discover what's next for the Moderate to Severe Atopic Dermatitis treatment landscape in this detailed analysis @ Moderate to Severe Atopic Dermatitis Emerging Drugs and Major Players

Table of Contents

1. Introduction

2. Executive Summary

3. Moderate to Severe Atopic Dermatitis: Overview

4. Pipeline Therapeutics

5. Therapeutic Assessment

6. Moderate to Severe Atopic Dermatitis– DelveInsight's Analytical Perspective

7. Late Stage Products (Phase III)

8. Cretostimogene grenadenorepvec: CG Oncology

9. Mid Stage Products (Phase II)

10. TYRA-300: Tyra Biosciences, Inc

11. Early Stage Products (Phase I)

12. UGN-301: UroGen Pharma Ltd.

13. Preclinical and Discovery Stage Products

14. Drug Name: Company Name

15. Inactive Products

16. Moderate to Severe Atopic Dermatitis Key Companies

17. Moderate to Severe Atopic Dermatitis Key Products

18. Moderate to Severe Atopic Dermatitis- Unmet Needs

19. Moderate to Severe Atopic Dermatitis- Market Drivers and Barriers

20. Moderate to Severe Atopic Dermatitis- Future Perspectives and Conclusion

21. Moderate to Severe Atopic Dermatitis Analyst Views

22. Moderate to Severe Atopic Dermatitis Key Companies

23. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

MENAFN08092025003238003268ID1110034026